Kainos Medicine, Inc. has begun a two-stage US Phase II study of an in-house developed novel Parkinson’s disease (PD) drug candidate KM-819, which the Korean biotech aims to develop as a disease modifying treatment for the neurodegenerative disease.
Kainos Progresses Parkinson’s Drug US Trials Amid Deal Prospects
US Phase II Study Of FAF1 Inhibitor Begins
Following ABL Bio’s sizable Parkinson’s disease drug deal with Sanofi early this year, Korean bioventure Kainos Medicine is under the spotlight as its novel PD drug candidate enters Phase II in the US.
